Gatifloxacin-Induced Hyperglycemia
Authors: Marc R. Happe, Brian P. Mulhall, Corinne L. Maydonovitch, Kent C. Holtzmuller
Journal: Annals of Internal Medicine (2004)

Letters21 December 2004Gatifloxacin-Induced HyperglycemiaMarc R. Happe, DO, Brian P. Mulhall, MD, Corinne L. Maydonovitch, BS, and Kent C. Holtzmuller, MDMarc R. Happe, DOFrom Walter Reed Army Medical Center, Washington, DC 20307.Search for more papers by this author, Brian P. Mulhall, MDFrom Walter Reed Army Medical Center, Washington, DC 20307.Search for more papers by this author, Corinne L. Maydonovitch, BSFrom Walter Reed Army Medical Center, Washington, DC 20307.Search for more papers by this author, and Kent C. Holtzmuller, MDFrom Walter Reed Army Medical Center, Washington, DC 20307.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-141-12-200412210-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Fourth-generation fluoroquinolones are broad-spectrum antibiotics frequently used to treat a wide variety of infections. Gatifloxacin (Tequin, Bristol-Myers Squibb, Princeton, New Jersey) is one of the newest and most effective quinolones (1). A small number of cases in the literature have shown significant abnormalities in glucose homeostasis after the administration of gatifloxacin (1-3). To date, only 1 case of hyperosmolar nonketotic hyperglycemia associated with gatifloxacin use has been published (2).Objective: To describe 2 patients with liver disease who developed severe hyperosmolar nonketotic hyperglycemia temporally related to the administration of gatifloxacin.Case Reports: Patient 1, a 60-year-old ...References1. Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother. 2003;52:435-40. [PMID: 12917247] CrossrefMedlineGoogle Scholar2. Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract. 2003;16:455-7. [PMID: 14645336] CrossrefMedlineGoogle Scholar3. Donaldson AR, Vandiver JR, Finch CK. Possible gatifloxacin-induced hyperglycemia. Ann Pharmacother. 2004;38:602-5. [PMID: 14982977] CrossrefMedlineGoogle Scholar4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. [PMID: 7249508] CrossrefMedlineGoogle Scholar5. Grasela DM, Christofalo B, Kollia GD, Duncan G, Noveck R, Manning JA, et al. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment. Pharmacotherapy. 2000;20:87S-94S. [PMID: 10850525] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Marc R. Happe, DO; Brian P. Mulhall, MD; Corinne L. Maydonovitch, BS; Kent C. Holtzmuller, MDAffiliations: From Walter Reed Army Medical Center, Washington, DC 20307.Disclaimer: The opinions or assertions contained herein are those of the authors and are not to be construed as official policy of the U.S. Department of the Army or the U.S. Department of Defense. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byGatifloxacinDysglycemia associated with quinolonesQuinolonesGatifloxacinChief complaint: altered mental statusANTIBACTERIAL DRUGSENDOCRINE AND METABOLIC ADVERSE EFFECTS OF NON-HORMONAL AND NON-METABOLIC DRUGSGatifloxacin-Induced Hyperglycemia: A Review of 4 Cases and the Literature26 Miscellaneous antibacterial drugsLevofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patientsGatifloxacin-induced hyperglycemia: A case report and summary of the current literatureGatifloxacin-induced dysglycemiaComparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infectionsOutpatient Gatifloxacin Therapy and Dysglycemia in Older AdultsFluctuating Blood Glucose Levels in an Elderly Diabetic PatientHyperglycemia in an Elderly Diabetic Patient: Drug-drug or Drug-disease Interaction?Effects of Gatifloxacin on Serum Glucose Concentration in Normal and Diabetic RatsGlucose Homeostasis Abnormalities Associated with Use of GatifloxacinA Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or CeftriaxoneSafety of Newer Parenteral AntibioticsSevere Hyperglycemia During Renally Adjusted Gatifloxacin TherapyCurrent awareness: Pharmacoepidemiology and drug safetyPulmonary Hypertension with Thalidomide Therapy; Hyperammonemia and Valproate; CNS Toxicity from Improper Use of Cyclopentolate Ophthalmic Drops; Glycemic Control Issues with Gatifloxacin; Infusion Phlebitis with Cyclosporine; Acute Hypersensitivity Reaction to HIV Fusion Inhibitor; Imatinib-Induced Hepatotoxicity 21 December 2004Volume 141, Issue 12Page: 968-699KeywordsDrugsGlucoseHemoglobinHyperglycemiaInsulinKetonesLiver diseasesPrimary sclerosing cholangitisResearch laboratoriesUrine ePublished: 21 December 2004 Issue Published: 21 December 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...